Testosterone Propionate Administration and Monitoring

Administration Routes

The American College of Physicians recommends intramuscular (IM) injection as the traditional and most common route for testosterone propionate administration, as supported by the Annals of Internal Medicine 1, 2

The American College of Physicians recommends monitoring hematocrit/hemoglobin regularly as testosterone therapy commonly causes erythrocytosis, particularly with injectable formulations, as reported in the New England Journal of Medicine 3, 4
The Endocrine Society suggests that if hematocrit rises above the reference range, consideration should be given to temporarily withholding therapy, reducing the dose, or performing phlebotomy, as recommended in the New England Journal of Medicine 5
Prostate monitoring is essential through digital rectal examination and PSA measurement before initiating therapy, with regular PSA monitoring during treatment, as advised in the New England Journal of Medicine 5

The American College of Physicians recommends adjusting the dose based on serum testosterone levels, aiming for the mid-normal range, as supported by the Annals of Internal Medicine 1, 2

The American Heart Association notes that erythrocytosis is more common with injectable testosterone formulations compared to topical preparations, as reported in the New England Journal of Medicine 3, 4
The National Lipid Association states that testosterone therapy appears to have a neutral effect on lipid profiles when used at physiologic replacement doses, as reported in the New England Journal of Medicine 3, 6
The American Urological Association indicates that while theoretical concerns exist regarding prostate health, evidence does not show significant exacerbation of benign prostatic hyperplasia symptoms during testosterone replacement therapy, as reported in the New England Journal of Medicine 4